Erratum: Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report (Pain Medicine (2019) 20: 4 (724-735) DOI: 10.1093/pm/pny307)

Kurt Kroenke; Daniel P. Alford; Charles Argoff; Bernard Canlas; Edward Covington; Joseph W. Frank; Karl J. Haake; Steven Hanling; W. Michael Hooten; Stefan G. Kertesz; Richard L. Kravitz; Erin E. Krebs; Steven P. Stanos; Mark Sullivan

doi:10.1093/pm/pnac105

Erratum: Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report (Pain Medicine (2019) 20: 4 (724-735) DOI: 10.1093/pm/pny307)

Kurt Kroenke, Daniel P. Alford, Charles Argoff, Bernard Canlas, Edward Covington, Joseph W. Frank, Karl J. Haake, Steven Hanling, W. Michael Hooten, Stefan G. Kertesz, Richard L. Kravitz, Erin E. Krebs, Steven P. Stanos, Mark Sullivan

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

After concerns were raised by a reader, the third author has disclosed extra competing interests in relation to this article. In addition to having served as a consultant for BioDelivery Sciences, Collegium, Daiichi Sankyo, Egalet, Grünenthal, Kaleo, US WorldMeds, Pfizer, Eli Lilly, Novartis, Scilex, Teva, and Regeneron and having received honoraria for speaking from Allergan, Daiichi Sankyo, Amgen, Teva, Eli Lilly, and Jazz Pharmaceuticals, Dr. Charles Argoff also received consulting fees from Purdue Pharma. The editors have since reviewed the article against the updated disclosure form and determined the article does not need to be peer reviewed again. The author apologizes for this inadvertent omission.

Original language	English (US)
Pages (from-to)	1636
Number of pages	1
Journal	Pain Medicine (United States)
Volume	23
Issue number	9
DOIs	https://doi.org/10.1093/pm/pnac105
State	Published - Sep 1 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1093/pm/pnac105

Find It

Find It at U of M Libraries

Cite this

Kroenke, K., Alford, D. P., Argoff, C., Canlas, B., Covington, E., Frank, J. W., Haake, K. J., Hanling, S., Hooten, W. M., Kertesz, S. G., Kravitz, R. L., Krebs, E. E., Stanos, S. P., & Sullivan, M. (2022). Erratum: Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report (Pain Medicine (2019) 20: 4 (724-735) DOI: 10.1093/pm/pny307). Pain Medicine (United States), 23(9), 1636. https://doi.org/10.1093/pm/pnac105

Erratum: Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report (Pain Medicine (2019) 20: 4 (724-735) DOI: 10.1093/pm/pny307). / Kroenke, Kurt; Alford, Daniel P.; Argoff, Charles et al.
In: Pain Medicine (United States), Vol. 23, No. 9, 01.09.2022, p. 1636.

Research output: Contribution to journal › Comment/debate › peer-review

Kroenke, K, Alford, DP, Argoff, C, Canlas, B, Covington, E, Frank, JW, Haake, KJ, Hanling, S, Hooten, WM, Kertesz, SG, Kravitz, RL, Krebs, EE, Stanos, SP & Sullivan, M 2022, 'Erratum: Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report (Pain Medicine (2019) 20: 4 (724-735) DOI: 10.1093/pm/pny307)', Pain Medicine (United States), vol. 23, no. 9, pp. 1636. https://doi.org/10.1093/pm/pnac105

@article{cca931df52024c85bfaa88eea53a3438,

title = "Erratum: Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report (Pain Medicine (2019) 20: 4 (724-735) DOI: 10.1093/pm/pny307)",

abstract = "After concerns were raised by a reader, the third author has disclosed extra competing interests in relation to this article. In addition to having served as a consultant for BioDelivery Sciences, Collegium, Daiichi Sankyo, Egalet, Gr{\"u}nenthal, Kaleo, US WorldMeds, Pfizer, Eli Lilly, Novartis, Scilex, Teva, and Regeneron and having received honoraria for speaking from Allergan, Daiichi Sankyo, Amgen, Teva, Eli Lilly, and Jazz Pharmaceuticals, Dr. Charles Argoff also received consulting fees from Purdue Pharma. The editors have since reviewed the article against the updated disclosure form and determined the article does not need to be peer reviewed again. The author apologizes for this inadvertent omission.",

author = "Kurt Kroenke and Alford, \{Daniel P.\} and Charles Argoff and Bernard Canlas and Edward Covington and Frank, \{Joseph W.\} and Haake, \{Karl J.\} and Steven Hanling and Hooten, \{W. Michael\} and Kertesz, \{Stefan G.\} and Kravitz, \{Richard L.\} and Krebs, \{Erin E.\} and Stanos, \{Steven P.\} and Mark Sullivan",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s).",

year = "2022",

month = sep,

day = "1",

doi = "10.1093/pm/pnac105",

language = "English (US)",

volume = "23",

pages = "1636",

journal = "Pain Medicine (United States)",

issn = "1526-2375",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Erratum

T2 - Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report (Pain Medicine (2019) 20: 4 (724-735) DOI: 10.1093/pm/pny307)

AU - Kroenke, Kurt

AU - Alford, Daniel P.

AU - Argoff, Charles

AU - Canlas, Bernard

AU - Covington, Edward

AU - Frank, Joseph W.

AU - Haake, Karl J.

AU - Hanling, Steven

AU - Hooten, W. Michael

AU - Kertesz, Stefan G.

AU - Kravitz, Richard L.

AU - Krebs, Erin E.

AU - Stanos, Steven P.

AU - Sullivan, Mark

PY - 2022/9/1

Y1 - 2022/9/1

N2 - After concerns were raised by a reader, the third author has disclosed extra competing interests in relation to this article. In addition to having served as a consultant for BioDelivery Sciences, Collegium, Daiichi Sankyo, Egalet, Grünenthal, Kaleo, US WorldMeds, Pfizer, Eli Lilly, Novartis, Scilex, Teva, and Regeneron and having received honoraria for speaking from Allergan, Daiichi Sankyo, Amgen, Teva, Eli Lilly, and Jazz Pharmaceuticals, Dr. Charles Argoff also received consulting fees from Purdue Pharma. The editors have since reviewed the article against the updated disclosure form and determined the article does not need to be peer reviewed again. The author apologizes for this inadvertent omission.

AB - After concerns were raised by a reader, the third author has disclosed extra competing interests in relation to this article. In addition to having served as a consultant for BioDelivery Sciences, Collegium, Daiichi Sankyo, Egalet, Grünenthal, Kaleo, US WorldMeds, Pfizer, Eli Lilly, Novartis, Scilex, Teva, and Regeneron and having received honoraria for speaking from Allergan, Daiichi Sankyo, Amgen, Teva, Eli Lilly, and Jazz Pharmaceuticals, Dr. Charles Argoff also received consulting fees from Purdue Pharma. The editors have since reviewed the article against the updated disclosure form and determined the article does not need to be peer reviewed again. The author apologizes for this inadvertent omission.

UR - https://www.scopus.com/pages/publications/85160210836

UR - https://www.scopus.com/inward/citedby.url?scp=85160210836&partnerID=8YFLogxK

U2 - 10.1093/pm/pnac105

DO - 10.1093/pm/pnac105

M3 - Comment/debate

C2 - 35791289

AN - SCOPUS:85160210836

SN - 1526-2375

VL - 23

SP - 1636

JO - Pain Medicine (United States)

JF - Pain Medicine (United States)

IS - 9

ER -

Erratum: Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report (Pain Medicine (2019) 20: 4 (724-735) DOI: 10.1093/pm/pny307)

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this